Search research articles
Contact Us
Filters
Showing results (1-10 of 26) with videos related to
Page
of 3
Sort By:
Frontiers in Immunology
|
July 23, 2020
Immunogenicity of Immunotoxins Containing <i>Pseudomonas</i> Exotoxin A: Causes, Consequences, and Mitigation
Ronit Mazor, Ira Pastan
The AAPS Journal
|
September 10, 2025
Can Sex-based Variations in the Immune Responses to AAV Gene Therapy Affect Safety and Efficacy? A Review of Current Understanding
Leila Abdelhamid, Ronit Mazor
Cellular Immunology
|
September 15, 2018
Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1
Ronit Mazor, Emily King, Ira Pastan
Immunological Reviews
|
February 12, 2016
Immunogenicity of therapeutic recombinant immunotoxins
Ronit Mazor, Masanori Onda, Ira Pastan
Frontiers in Immunology
|
July 20, 2023
Low cross reactivity between wild type and deamidated AAV can lead to false negative results in immune monitoring T-cell assays
So Jin Bing, Stephanee Warrington, Ronit Mazor
The American Journal of Pathology
|
June 6, 2018
Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins
Ronit Mazor, Emily M King, Ira Pastan
Journal of Immunology (Baltimore, Md. : 1950)
|
February 13, 2018
Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin
Emily M King, Ronit Mazor, Nicolas Çuburu, et al.
Journal of Immunological Methods
|
June 10, 2015
Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A
Ronit Mazor, Chin-Hsien Tai, Byungkook Lee, et al.
Toxins
|
November 17, 2018
SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors
Yasmin Leshem, Emily M King, Ronit Mazor, et al.
Molecular Cancer Therapeutics
|
April 27, 2018
Improving the <i>In Vivo</i> Efficacy of an Anti-Tac (CD25) Immunotoxin by <i>Pseudomonas</i> Exotoxin A Domain II Engineering
Gilad Kaplan, Ronit Mazor, Fred Lee, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 26) with videos related to
Sort By:
Page
of 3
Frontiers in Immunology
|
July 23, 2020
Immunogenicity of Immunotoxins Containing <i>Pseudomonas</i> Exotoxin A: Causes, Consequences, and Mitigation
Ronit Mazor, Ira Pastan
The AAPS Journal
|
September 10, 2025
Can Sex-based Variations in the Immune Responses to AAV Gene Therapy Affect Safety and Efficacy? A Review of Current Understanding
Leila Abdelhamid, Ronit Mazor
Cellular Immunology
|
September 15, 2018
Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1
Ronit Mazor, Emily King, Ira Pastan
Immunological Reviews
|
February 12, 2016
Immunogenicity of therapeutic recombinant immunotoxins
Ronit Mazor, Masanori Onda, Ira Pastan
Frontiers in Immunology
|
July 20, 2023
Low cross reactivity between wild type and deamidated AAV can lead to false negative results in immune monitoring T-cell assays
So Jin Bing, Stephanee Warrington, Ronit Mazor
The American Journal of Pathology
|
June 6, 2018
Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins
Ronit Mazor, Emily M King, Ira Pastan
Journal of Immunology (Baltimore, Md. : 1950)
|
February 13, 2018
Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin
Emily M King, Ronit Mazor, Nicolas Çuburu, et al.
Journal of Immunological Methods
|
June 10, 2015
Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A
Ronit Mazor, Chin-Hsien Tai, Byungkook Lee, et al.
Toxins
|
November 17, 2018
SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors
Yasmin Leshem, Emily M King, Ronit Mazor, et al.
Molecular Cancer Therapeutics
|
April 27, 2018
Improving the <i>In Vivo</i> Efficacy of an Anti-Tac (CD25) Immunotoxin by <i>Pseudomonas</i> Exotoxin A Domain II Engineering
Gilad Kaplan, Ronit Mazor, Fred Lee, et al.
Page
of 3